altacor-pharma.com
Altacor - Senior Management
http://www.altacor-pharma.com/senior-management
Director of Sales and Marketing.
altacor-pharma.com
Altacor - Partnering
http://www.altacor-pharma.com/partnering
Altacor’s partnering strategy has two key elements:. Commercialisation of its current product portfolio (including future pipeline products) outside of Europe via partnerships with specialty ophthalmology companies; and. Enhancing its ophthalmology portfolio for commercialisation in Europe through its own sales force, by accessing products (via in-licensing or acquiring rights) through relationships with partners in the US or in other countries outside Europe who market them in their home territories.
altacor-pharma.com
Altacor - Media
http://www.altacor-pharma.com/media
Mar 30, 2016. Altacor add BioLon to its growing portfolio Read more. Aug 1, 2014. Altacor growth to accelerate after strategic acquisition by Esperante BV Read more. Jul 1, 2013. Altacor strengthens commercial capability with Norgine collaboration Read more. Jun 8, 2013. Three out of four patients don't need to be here' say eye clinics Read more. Mar 6, 2013. Altacor puts the heat on blepharitis Read more. Feb 25, 2013. Dry eye awareness improves patient experience Read more. Feb 1, 2013. Jan 21, 2013.
altacor-pharma.com
Altacor - Marketed Products
http://www.altacor-pharma.com/marketed-products
Altacor’s current product range comprises around four product categories,. The prevalence of DES increases with age, and approximately 10% of adults over the age of 40 years suffer from Dry Eye. The objective for the treatment of DES is improvement in tear production and quality. Dry Eye Prescription Products. Clinitas and Clinitas Multi Rx. Dry Eye Retail Products. Clinitas Soothe and Clinitas Soothe Multi. Clinitas Soothe and Clinitas Soothe Multi are retail versions of Clinitas Rx. It is stocked i...
altacor-pharma.com
Altacor - Investors
http://www.altacor-pharma.com/investors
Altacor is creating a leading European specialty ophthalmology company developing and marketing a portfolio of reprofiled, low-risk and/or orphan products targeting chronic eye conditions through its own specialist sales force. The Company was co-founded by Dr Francesca Crawford in 2005 has since raised, in aggregate, circa 10 million through a number of funding rounds that were supported by a combination of venture funds alongside sophisticated angels, high net worth and other investors.
altacor-pharma.com
Altacor - Board of Directors
http://www.altacor-pharma.com/board-of-directors
Managing Director, Esperante Ventures.
altacor-pharma.com
Altacor - Home
http://www.altacor-pharma.com/home
Altacor is creating a leading European specialty ophthalmology company. The Company markets and develops a portfolio of reprofiled, low-risk and orphan products targeting chronic eye conditions through its own specialist sales force. Mar 30, 2016. Altacor add BioLon to its growing portfolio. Aug 1, 2014. Altacor growth to accelerate after strategic acquisition by Esperante BV. 20th and 21st October 2016. The Millennium Gloucester Hotel, London. 25th and 26th September 2016.
altacor-pharma.com
Altacor - Product Portfolio
http://www.altacor-pharma.com/product-portfolio
Altacor currently markets products in the Dry Eye and other (Blepharitis) segments. In addition, Altacor has nutritional supplement in the retinal segment for the prevention of progression of dry age-related macular degeneration (AMD). R&D pipeline programmes covering surgery and glaucoma are in progress. Altacor’s product pipeline is supported variously by patents, orphan designations, licences, know-how and trademarks.
altacor-pharma.com
Altacor - About
http://www.altacor-pharma.com/about
Altacor is creating a leading European specialty ophthalmology company developing and marketing a portfolio of reprofiled, low-risk and/or orphan products targeting chronic eye conditions through its own specialist sales force. The Company’s strategy is to build its product base and commercial organisation into major countries in Europe through transactions and partnerships. The global ophthalmology market is growing strongly and is expected to rise from US$18bn in 2012 to over US$23bn in 2016*. This...
altacor-pharma.com
Altacor - Pipeline
http://www.altacor-pharma.com/pipeline
Altacor’s pipeline targets important and fast-growing areas of the ophthalmology market, including glaucoma, glaucoma surgery and cataract surgery. The most common form of glaucoma is primary open-angle glaucoma (POAG) and this is initially treated with long-term use of eye drops containing drugs designed to lower IOP. Altacor has two projects for glaucoma, one with a novel patented mechanism of action, and the second for steroid-induced glaucoma. ALT 401 Prevention of Scarring Following Glaucoma Surgery.